1	A	_	DT	_	_	4	NMOD	_	_
2	proposed	_	VBN	_	_	4	NMOD	_	_
3	conflict-of-interest	_	NN	_	_	4	NMOD	_	_
4	policy	_	NN	_	_	10	SBJ	_	_
5	for	_	IN	_	_	4	NMOD	_	_
6	federally	_	RB	_	_	7	AMOD	_	_
7	funded	_	VBN	_	_	9	NMOD	_	_
8	biomedical	_	JJ	_	_	9	NMOD	_	_
9	researchers	_	NNS	_	_	5	PMOD	_	_
10	may	_	MD	_	_	17	OBJ	_	_
11	thwart	_	VB	_	_	10	VC	_	_
12	many	_	JJ	_	_	15	NMOD	_	_
13	high-technology	_	NN	_	_	15	NMOD	_	_
14	new	_	JJ	_	_	15	NMOD	_	_
15	ventures	_	NNS	_	_	11	OBJ	_	_
16	,	_	,	_	_	17	P	_	_
17	say	_	VBP	_	_	0	ROOT	_	_
18	financiers	_	NNS	_	_	17	SBJ	_	_
19	,	_	,	_	_	18	P	_	_
20	researchers	_	NNS	_	_	18	COORD	_	_
21	and	_	CC	_	_	20	COORD	_	_
22	university	_	NN	_	_	23	NMOD	_	_
23	administrators	_	NNS	_	_	21	CONJ	_	_
24	.	_	.	_	_	17	P	_	_

1	The	_	DT	_	_	6	NMOD	_	_
2	National	_	NNP	_	_	3	NAME	_	_
3	Institutes	_	NNPS	_	_	6	NMOD	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	Health	_	NNP	_	_	4	PMOD	_	_
6	policy	_	NN	_	_	7	SBJ	_	_
7	would	_	MD	_	_	0	ROOT	_	_
8	require	_	VB	_	_	7	VC	_	_
9	researchers	_	NNS	_	_	8	OBJ	_	_
10	to	_	TO	_	_	8	OPRD	_	_
11	cut	_	VB	_	_	10	IM	_	_
12	financial	_	JJ	_	_	13	NMOD	_	_
13	ties	_	NNS	_	_	11	OBJ	_	_
14	with	_	IN	_	_	13	NMOD	_	_
15	health-care	_	JJ	_	_	16	NMOD	_	_
16	businesses	_	NNS	_	_	14	PMOD	_	_
17	--	_	:	_	_	11	P	_	_
18	or	_	CC	_	_	11	COORD	_	_
19	lose	_	VB	_	_	18	CONJ	_	_
20	their	_	PRP$	_	_	22	NMOD	_	_
21	government	_	NN	_	_	22	NMOD	_	_
22	money	_	NN	_	_	19	OBJ	_	_
23	.	_	.	_	_	7	P	_	_

1	Among	_	IN	_	_	7	ADV	_	_
2	other	_	JJ	_	_	3	NMOD	_	_
3	concerns	_	NNS	_	_	1	PMOD	_	_
4	,	_	,	_	_	7	P	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	agency	_	NN	_	_	7	SBJ	_	_
7	says	_	VBZ	_	_	0	ROOT	_	_
8	researchers	_	NNS	_	_	12	SBJ	_	_
9	with	_	IN	_	_	8	NMOD	_	_
10	business	_	NN	_	_	11	NMOD	_	_
11	ties	_	NNS	_	_	9	PMOD	_	_
12	are	_	VBP	_	_	7	OBJ	_	_
13	more	_	RBR	_	_	14	AMOD	_	_
14	likely	_	JJ	_	_	12	PRD	_	_
15	to	_	TO	_	_	14	AMOD	_	_
16	falsify	_	VB	_	_	15	IM	_	_
17	findings	_	NNS	_	_	16	OBJ	_	_
18	in	_	IN	_	_	16	PRP	_	_
19	order	_	NN	_	_	18	DEP	_	_
20	to	_	TO	_	_	18	SUB	_	_
21	tout	_	VB	_	_	20	IM	_	_
22	new	_	JJ	_	_	23	NMOD	_	_
23	drugs	_	NNS	_	_	21	OBJ	_	_
24	.	_	.	_	_	7	P	_	_

1	As	_	IN	_	_	18	TMP	_	_
2	ties	_	NNS	_	_	8	SBJ	_	_
3	between	_	IN	_	_	2	NMOD	_	_
4	academia	_	NN	_	_	3	PMOD	_	_
5	and	_	CC	_	_	4	COORD	_	_
6	venture	_	NN	_	_	7	NMOD	_	_
7	capital	_	NN	_	_	5	CONJ	_	_
8	have	_	VBP	_	_	1	SUB	_	_
9	blossomed	_	VBN	_	_	8	VC	_	_
10	in	_	IN	_	_	9	TMP	_	_
11	recent	_	JJ	_	_	12	NMOD	_	_
12	years	_	NNS	_	_	10	PMOD	_	_
13	,	_	,	_	_	18	P	_	_
14	governmental	_	JJ	_	_	15	NMOD	_	_
15	fear	_	NN	_	_	18	SBJ	_	_
16	of	_	IN	_	_	15	NMOD	_	_
17	abuse	_	NN	_	_	16	PMOD	_	_
18	has	_	VBZ	_	_	0	ROOT	_	_
19	risen	_	VBN	_	_	18	VC	_	_
20	.	_	.	_	_	18	P	_	_

1	But	_	CC	_	_	4	DEP	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	guidelines	_	NNS	_	_	4	SBJ	_	_
4	could	_	MD	_	_	14	OBJ	_	_
5	``	_	``	_	_	4	P	_	_
6	make	_	VB	_	_	4	VC	_	_
7	it	_	PRP	_	_	6	OBJ	_	_
8	impossible	_	JJ	_	_	6	OPRD	_	_
9	to	_	TO	_	_	8	EXTR	_	_
10	commercialize	_	VB	_	_	9	IM	_	_
11	research	_	NN	_	_	10	OBJ	_	_
12	,	_	,	_	_	14	P	_	_
13	''	_	''	_	_	14	P	_	_
14	says	_	VBZ	_	_	0	ROOT	_	_
15	Kenneth	_	NNP	_	_	16	NAME	_	_
16	Smith	_	NNP	_	_	14	SBJ	_	_
17	,	_	,	_	_	16	P	_	_
18	associate	_	JJ	_	_	19	NMOD	_	_
19	provost	_	NN	_	_	16	APPO	_	_
20	and	_	CC	_	_	19	COORD	_	_
21	vice	_	NN	_	_	22	NMOD	_	_
22	president	_	NN	_	_	20	CONJ	_	_
23	for	_	IN	_	_	22	NMOD	_	_
24	research	_	NN	_	_	23	PMOD	_	_
25	at	_	IN	_	_	19	LOC	_	_
26	Massachusetts	_	NNP	_	_	27	NAME	_	_
27	Institute	_	NNP	_	_	25	PMOD	_	_
28	of	_	IN	_	_	27	NMOD	_	_
29	Technology	_	NNP	_	_	28	PMOD	_	_
30	.	_	.	_	_	14	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	NIH	_	NNP	_	_	3	SBJ	_	_
3	is	_	VBZ	_	_	0	ROOT	_	_
4	asking	_	VBG	_	_	3	VC	_	_
5	grant	_	NN	_	_	6	NMOD	_	_
6	recipients	_	NNS	_	_	4	OBJ	_	_
7	and	_	CC	_	_	6	COORD	_	_
8	others	_	NNS	_	_	7	CONJ	_	_
9	for	_	IN	_	_	4	ADV	_	_
10	comments	_	NNS	_	_	9	PMOD	_	_
11	on	_	IN	_	_	10	NMOD	_	_
12	the	_	DT	_	_	14	NMOD	_	_
13	proposed	_	VBN	_	_	14	NMOD	_	_
14	guidelines	_	NNS	_	_	11	PMOD	_	_
15	until	_	IN	_	_	4	TMP	_	_
16	Dec.	_	NNP	_	_	15	PMOD	_	_
17	15	_	CD	_	_	16	NMOD	_	_
18	.	_	.	_	_	3	P	_	_

1	After	_	IN	_	_	5	TMP	_	_
2	that	_	DT	_	_	1	PMOD	_	_
3	,	_	,	_	_	5	P	_	_
4	it	_	PRP	_	_	5	SBJ	_	_
5	will	_	MD	_	_	0	ROOT	_	_
6	make	_	VB	_	_	5	VC	_	_
7	a	_	DT	_	_	9	NMOD	_	_
8	final	_	JJ	_	_	9	NMOD	_	_
9	decision	_	NN	_	_	6	OBJ	_	_
10	on	_	IN	_	_	9	NMOD	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	policy	_	NN	_	_	10	PMOD	_	_
13	.	_	.	_	_	5	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	guidelines	_	NNS	_	_	3	SBJ	_	_
3	could	_	MD	_	_	22	OBJ	_	_
4	foil	_	VB	_	_	3	VC	_	_
5	future	_	JJ	_	_	6	NMOD	_	_
6	arrangements	_	NNS	_	_	4	OBJ	_	_
7	similar	_	JJ	_	_	6	APPO	_	_
8	to	_	TO	_	_	7	AMOD	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	deal	_	NN	_	_	8	PMOD	_	_
11	behind	_	IN	_	_	10	NMOD	_	_
12	Lithox	_	NNP	_	_	11	PMOD	_	_
13	Inc.	_	NNP	_	_	12	POSTHON	_	_
14	,	_	,	_	_	12	P	_	_
15	a	_	DT	_	_	20	NMOD	_	_
16	Salem	_	NNP	_	_	18	NAME	_	_
17	,	_	,	_	_	18	P	_	_
18	Mass.	_	NNP	_	_	20	LOC	_	_
19	,	_	,	_	_	18	P	_	_
20	start-up	_	NN	_	_	12	APPO	_	_
21	,	_	,	_	_	22	P	_	_
22	says	_	VBZ	_	_	0	ROOT	_	_
23	Robert	_	NNP	_	_	24	NAME	_	_
24	Daly	_	NNP	_	_	22	SBJ	_	_
25	,	_	,	_	_	24	P	_	_
26	a	_	DT	_	_	28	NMOD	_	_
27	managing	_	VBG	_	_	28	NMOD	_	_
28	partner	_	NN	_	_	24	APPO	_	_
29	of	_	IN	_	_	28	NMOD	_	_
30	TA	_	NNP	_	_	31	NAME	_	_
31	Associates	_	NNPS	_	_	29	PMOD	_	_
32	,	_	,	_	_	31	P	_	_
33	a	_	DT	_	_	35	NMOD	_	_
34	venture-capital	_	JJ	_	_	35	NMOD	_	_
35	firm	_	NN	_	_	31	APPO	_	_
36	.	_	.	_	_	22	P	_	_

1	With	_	IN	_	_	10	ADV	_	_
2	$	_	$	_	_	1	PMOD	_	_
3	2.3	_	CD	_	_	2	DEP	_	_
4	million	_	CD	_	_	2	DEP	_	_
5	,	_	,	_	_	10	P	_	_
6	he	_	PRP	_	_	10	SBJ	_	_
7	and	_	CC	_	_	6	COORD	_	_
8	other	_	JJ	_	_	9	NMOD	_	_
9	investors	_	NNS	_	_	7	CONJ	_	_
10	launched	_	VBD	_	_	0	ROOT	_	_
11	Lithox	_	NNP	_	_	10	OBJ	_	_
12	last	_	JJ	_	_	13	NMOD	_	_
13	year	_	NN	_	_	10	TMP	_	_
14	to	_	TO	_	_	10	PRP	_	_
15	market	_	NN	_	_	14	IM	_	_
16	a	_	DT	_	_	18	NMOD	_	_
17	gallstone	_	NN	_	_	18	NMOD	_	_
18	cure	_	NN	_	_	15	OBJ	_	_
19	being	_	NN	_	_	20	DEP	_	_
20	developed	_	VBN	_	_	18	APPO	_	_
21	by	_	IN	_	_	20	LGS	_	_
22	researchers	_	NNS	_	_	21	PMOD	_	_
23	of	_	IN	_	_	22	NMOD	_	_
24	the	_	DT	_	_	25	NMOD	_	_
25	University	_	NNP	_	_	23	PMOD	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	California	_	NNP	_	_	26	PMOD	_	_
28	at	_	IN	_	_	25	LOC	_	_
29	San	_	NNP	_	_	30	NAME	_	_
30	Diego	_	NNP	_	_	28	PMOD	_	_
31	.	_	.	_	_	10	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	researchers	_	NNS	_	_	13	SBJ	_	_
3	,	_	,	_	_	2	P	_	_
4	who	_	WP	_	_	5	SBJ	_	_
5	are	_	VBP	_	_	2	NMOD	_	_
6	being	_	VBG	_	_	5	VC	_	_
7	financed	_	VBN	_	_	6	VC	_	_
8	by	_	IN	_	_	7	LGS	_	_
9	the	_	DT	_	_	11	NMOD	_	_
10	Lithox	_	NNP	_	_	11	NMOD	_	_
11	funds	_	NNS	_	_	8	PMOD	_	_
12	,	_	,	_	_	2	P	_	_
13	will	_	MD	_	_	0	ROOT	_	_
14	receive	_	VB	_	_	13	VC	_	_
15	a	_	DT	_	_	16	NMOD	_	_
16	royalty	_	NN	_	_	14	OBJ	_	_
17	,	_	,	_	_	16	P	_	_
18	or	_	CC	_	_	16	COORD	_	_
19	percentage	_	NN	_	_	18	CONJ	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	sales	_	NNS	_	_	20	PMOD	_	_
22	,	_	,	_	_	16	P	_	_
23	if	_	IN	_	_	14	ADV	_	_
24	their	_	PRP$	_	_	25	NMOD	_	_
25	research	_	NN	_	_	26	SBJ	_	_
26	yields	_	VBZ	_	_	23	SUB	_	_
27	a	_	DT	_	_	29	NMOD	_	_
28	commercial	_	JJ	_	_	29	NMOD	_	_
29	product	_	NN	_	_	26	OBJ	_	_
30	.	_	.	_	_	13	P	_	_

1	But	_	CC	_	_	20	DEP	_	_
2	because	_	IN	_	_	20	PRP	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	University	_	NNP	_	_	13	SBJ	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	California	_	NNP	_	_	5	PMOD	_	_
7	,	_	,	_	_	13	P	_	_
8	like	_	IN	_	_	13	ADV	_	_
9	many	_	JJ	_	_	11	NMOD	_	_
10	other	_	JJ	_	_	11	NMOD	_	_
11	universities	_	NNS	_	_	8	PMOD	_	_
12	,	_	,	_	_	13	P	_	_
13	shares	_	VBZ	_	_	2	SUB	_	_
14	its	_	PRP$	_	_	15	NMOD	_	_
15	royalties	_	NNS	_	_	13	OBJ	_	_
16	with	_	IN	_	_	13	ADV	_	_
17	researchers	_	NNS	_	_	16	PMOD	_	_
18	,	_	,	_	_	20	P	_	_
19	it	_	PRP	_	_	20	SBJ	_	_
20	may	_	MD	_	_	33	OBJ	_	_
21	disqualify	_	VB	_	_	20	VC	_	_
22	itself	_	PRP	_	_	21	OBJ	_	_
23	from	_	IN	_	_	21	ADV	_	_
24	federal	_	JJ	_	_	25	NMOD	_	_
25	funds	_	NNS	_	_	23	PMOD	_	_
26	under	_	IN	_	_	21	LOC	_	_
27	the	_	DT	_	_	29	NMOD	_	_
28	proposed	_	VBN	_	_	29	NMOD	_	_
29	guidelines	_	NNS	_	_	26	PMOD	_	_
30	,	_	,	_	_	20	P	_	_
31	Mr.	_	NNP	_	_	32	TITLE	_	_
32	Daly	_	NNP	_	_	33	SBJ	_	_
33	says	_	VBZ	_	_	0	ROOT	_	_
34	.	_	.	_	_	33	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	high-tech	_	JJ	_	_	3	NMOD	_	_
3	industry	_	NN	_	_	4	SBJ	_	_
4	is	_	VBZ	_	_	0	ROOT	_	_
5	full	_	JJ	_	_	4	PRD	_	_
6	of	_	IN	_	_	5	AMOD	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	kind	_	NN	_	_	6	PMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	arrangement	_	NN	_	_	9	PMOD	_	_
11	that	_	IN	_	_	16	OBJ	_	_
12	the	_	DT	_	_	14	NMOD	_	_
13	new	_	JJ	_	_	14	NMOD	_	_
14	guidelines	_	NNS	_	_	15	SBJ	_	_
15	would	_	MD	_	_	8	NMOD	_	_
16	affect	_	VB	_	_	15	VC	_	_
17	.	_	.	_	_	4	P	_	_

1	For	_	IN	_	_	14	ADV	_	_
2	instance	_	NN	_	_	1	PMOD	_	_
3	,	_	,	_	_	14	P	_	_
4	Commonwealth	_	NNP	_	_	5	NAME	_	_
5	BioVentures	_	NNP	_	_	14	SBJ	_	_
6	Inc.	_	NNP	_	_	5	POSTHON	_	_
7	,	_	,	_	_	5	P	_	_
8	a	_	DT	_	_	10	NMOD	_	_
9	venture-capital	_	JJ	_	_	10	NMOD	_	_
10	concern	_	NN	_	_	5	APPO	_	_
11	,	_	,	_	_	5	P	_	_
12	last	_	JJ	_	_	13	NMOD	_	_
13	month	_	NN	_	_	14	TMP	_	_
14	invested	_	VBD	_	_	0	ROOT	_	_
15	$	_	$	_	_	14	OBJ	_	_
16	600,000	_	CD	_	_	15	NMOD	_	_
17	to	_	TO	_	_	14	PRP	_	_
18	launch	_	VB	_	_	17	IM	_	_
19	Amira	_	NNP	_	_	18	OBJ	_	_
20	Inc.	_	NNP	_	_	19	POSTHON	_	_
21	,	_	,	_	_	19	P	_	_
22	a	_	DT	_	_	27	NMOD	_	_
23	Worcester	_	NNP	_	_	25	NAME	_	_
24	,	_	,	_	_	25	P	_	_
25	Mass.	_	NNP	_	_	27	LOC	_	_
26	,	_	,	_	_	25	P	_	_
27	concern	_	NN	_	_	19	APPO	_	_
28	that	_	WDT	_	_	29	SBJ	_	_
29	will	_	MD	_	_	27	NMOD	_	_
30	produce	_	VB	_	_	29	VC	_	_
31	pharmaceuticals	_	NNS	_	_	30	OBJ	_	_
32	.	_	.	_	_	14	P	_	_

1	Scientists	_	NNS	_	_	3	NMOD	_	_
2	Rima	_	NNP	_	_	3	NAME	_	_
3	Kaddurah-Daouk	_	NNP	_	_	7	SBJ	_	_
4	and	_	CC	_	_	3	COORD	_	_
5	Paul	_	NNP	_	_	6	NAME	_	_
6	Schimmel	_	NNP	_	_	4	CONJ	_	_
7	conducted	_	VBD	_	_	0	ROOT	_	_
8	the	_	DT	_	_	10	NMOD	_	_
9	initial	_	JJ	_	_	10	NMOD	_	_
10	research	_	NN	_	_	7	OBJ	_	_
11	at	_	IN	_	_	7	LOC	_	_
12	the	_	DT	_	_	14	NMOD	_	_
13	Massachusetts	_	NNP	_	_	14	NAME	_	_
14	Institute	_	NNP	_	_	11	PMOD	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	Technology	_	NNP	_	_	15	PMOD	_	_
17	.	_	.	_	_	7	P	_	_

1	While	_	IN	_	_	12	ADV	_	_
2	Ms.	_	NNP	_	_	3	TITLE	_	_
3	Kaddurah-Daouk	_	NNP	_	_	4	SBJ	_	_
4	left	_	VBD	_	_	1	SUB	_	_
5	MIT	_	NNP	_	_	4	OBJ	_	_
6	to	_	TO	_	_	4	PRP	_	_
7	head	_	VB	_	_	6	IM	_	_
8	Amira	_	NNP	_	_	7	OBJ	_	_
9	,	_	,	_	_	12	P	_	_
10	Prof.	_	NNP	_	_	11	TITLE	_	_
11	Schimmel	_	NNP	_	_	12	SBJ	_	_
12	will	_	MD	_	_	0	ROOT	_	_
13	continue	_	VB	_	_	12	VC	_	_
14	to	_	TO	_	_	13	OPRD	_	_
15	work	_	VB	_	_	14	IM	_	_
16	at	_	IN	_	_	15	LOC	_	_
17	MIT	_	NNP	_	_	16	PMOD	_	_
18	,	_	,	_	_	15	P	_	_
19	serve	_	VB	_	_	15	COORD	_	_
20	on	_	IN	_	_	19	ADV	_	_
21	Amira	_	NNP	_	_	23	NMOD	_	_
22	's	_	POS	_	_	21	SUFFIX	_	_
23	board	_	NN	_	_	20	PMOD	_	_
24	and	_	CC	_	_	19	COORD	_	_
25	own	_	VB	_	_	24	CONJ	_	_
26	a	_	DT	_	_	29	NMOD	_	_
27	small	_	JJ	_	_	29	NMOD	_	_
28	equity	_	NN	_	_	29	NMOD	_	_
29	stake	_	NN	_	_	25	OBJ	_	_
30	in	_	IN	_	_	29	NMOD	_	_
31	the	_	DT	_	_	32	NMOD	_	_
32	company	_	NN	_	_	30	PMOD	_	_
33	.	_	.	_	_	12	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	Amira	_	NNP	_	_	3	NMOD	_	_
3	transaction	_	NN	_	_	4	SBJ	_	_
4	is	_	VBZ	_	_	0	ROOT	_	_
5	typical	_	JJ	_	_	4	PRD	_	_
6	of	_	IN	_	_	5	AMOD	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	way	_	NN	_	_	6	PMOD	_	_
9	venture-capital	_	JJ	_	_	10	NMOD	_	_
10	firms	_	NNS	_	_	11	SBJ	_	_
11	are	_	VBP	_	_	8	NMOD	_	_
12	approaching	_	VBG	_	_	11	VC	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	task	_	NN	_	_	12	OBJ	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	commercializing	_	VBG	_	_	15	PMOD	_	_
17	biotechnology	_	NN	_	_	18	NMOD	_	_
18	research	_	NN	_	_	16	OBJ	_	_
19	.	_	.	_	_	4	P	_	_

1	While	_	IN	_	_	11	ADV	_	_
2	universities	_	NNS	_	_	3	SBJ	_	_
3	develop	_	VBP	_	_	1	SUB	_	_
4	the	_	DT	_	_	6	NMOD	_	_
5	basic	_	JJ	_	_	6	NMOD	_	_
6	research	_	NN	_	_	3	OBJ	_	_
7	,	_	,	_	_	11	P	_	_
8	``	_	``	_	_	11	P	_	_
9	venture	_	NN	_	_	10	NMOD	_	_
10	capitalists	_	NNS	_	_	11	SBJ	_	_
11	are	_	VBP	_	_	22	OBJ	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	ones	_	NNS	_	_	11	PRD	_	_
14	best	_	RB	_	_	15	ADV	_	_
15	positioned	_	VBD	_	_	13	APPO	_	_
16	to	_	TO	_	_	15	OPRD	_	_
17	finance	_	VB	_	_	16	IM	_	_
18	its	_	PRP$	_	_	19	NMOD	_	_
19	commercialization	_	NN	_	_	17	OBJ	_	_
20	,	_	,	_	_	22	P	_	_
21	''	_	''	_	_	22	P	_	_
22	says	_	VBZ	_	_	0	ROOT	_	_
23	Gloria	_	NNP	_	_	25	NAME	_	_
24	W.	_	NNP	_	_	25	NAME	_	_
25	Doubleday	_	NNP	_	_	22	SBJ	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	Commonwealth	_	NNP	_	_	26	PMOD	_	_
28	.	_	.	_	_	22	P	_	_

1	``	_	``	_	_	3	P	_	_
2	This	_	DT	_	_	3	SBJ	_	_
3	is	_	VBZ	_	_	0	ROOT	_	_
4	the	_	DT	_	_	6	NMOD	_	_
5	best	_	JJS	_	_	6	NMOD	_	_
6	way	_	NN	_	_	3	PRD	_	_
7	to	_	TO	_	_	6	NMOD	_	_
8	transfer	_	VB	_	_	7	IM	_	_
9	technology	_	NN	_	_	8	OBJ	_	_
10	straight	_	RB	_	_	11	DEP	_	_
11	off	_	IN	_	_	8	ADV	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	campuses	_	NNS	_	_	11	PMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	universities	_	NNS	_	_	14	PMOD	_	_
16	.	_	.	_	_	3	P	_	_
17	''	_	''	_	_	3	P	_	_

1	But	_	CC	_	_	5	DEP	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	new	_	JJ	_	_	4	NMOD	_	_
4	guidelines	_	NNS	_	_	5	SBJ	_	_
5	could	_	MD	_	_	22	OBJ	_	_
6	prevent	_	VB	_	_	5	VC	_	_
7	scientists	_	NNS	_	_	6	OBJ	_	_
8	like	_	IN	_	_	7	NMOD	_	_
9	Prof.	_	NNP	_	_	10	TITLE	_	_
10	Schimmel	_	NNP	_	_	8	PMOD	_	_
11	from	_	IN	_	_	6	ADV	_	_
12	being	_	VBG	_	_	11	PMOD	_	_
13	involved	_	VBN	_	_	12	VC	_	_
14	with	_	IN	_	_	13	ADV	_	_
15	start-ups	_	NNS	_	_	14	PMOD	_	_
16	such	_	JJ	_	_	17	DEP	_	_
17	as	_	IN	_	_	15	NMOD	_	_
18	Amira	_	NNP	_	_	17	PMOD	_	_
19	,	_	,	_	_	5	P	_	_
20	venture	_	NN	_	_	21	NMOD	_	_
21	capitalists	_	NNS	_	_	22	SBJ	_	_
22	point	_	VBP	_	_	0	ROOT	_	_
23	out	_	RP	_	_	22	PRT	_	_
24	.	_	.	_	_	22	P	_	_

1	And	_	CC	_	_	15	DEP	_	_
2	if	_	IN	_	_	15	ADV	_	_
3	that	_	DT	_	_	4	SBJ	_	_
4	happens	_	VBZ	_	_	2	SUB	_	_
5	,	_	,	_	_	15	P	_	_
6	the	_	DT	_	_	8	NMOD	_	_
7	entire	_	JJ	_	_	8	NMOD	_	_
8	process	_	NN	_	_	15	SBJ	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	transferring	_	VBG	_	_	9	PMOD	_	_
11	technology	_	NN	_	_	10	OBJ	_	_
12	to	_	TO	_	_	10	DIR	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	marketplace	_	NN	_	_	12	PMOD	_	_
15	could	_	MD	_	_	20	OBJ	_	_
16	be	_	VB	_	_	15	VC	_	_
17	harmed	_	VBN	_	_	16	VC	_	_
18	,	_	,	_	_	15	P	_	_
19	they	_	PRP	_	_	20	SBJ	_	_
20	say	_	VBP	_	_	0	ROOT	_	_
21	.	_	.	_	_	20	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	stakes	_	NNS	_	_	6	SBJ	_	_
3	in	_	IN	_	_	2	LOC	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	controversy	_	NN	_	_	3	PMOD	_	_
6	are	_	VBP	_	_	0	ROOT	_	_
7	large	_	JJ	_	_	6	PRD	_	_
8	.	_	.	_	_	6	P	_	_

1	Last	_	JJ	_	_	2	NMOD	_	_
2	year	_	NN	_	_	6	TMP	_	_
3	,	_	,	_	_	6	P	_	_
4	venture	_	NN	_	_	5	NMOD	_	_
5	capitalists	_	NNS	_	_	6	SBJ	_	_
6	spent	_	VBD	_	_	0	ROOT	_	_
7	an	_	DT	_	_	9	NMOD	_	_
8	estimated	_	VBN	_	_	9	DEP	_	_
9	$	_	$	_	_	6	OBJ	_	_
10	600	_	CD	_	_	9	DEP	_	_
11	million	_	CD	_	_	9	DEP	_	_
12	to	_	TO	_	_	6	PRP	_	_
13	finance	_	VB	_	_	12	IM	_	_
14	start-up	_	JJ	_	_	15	NMOD	_	_
15	companies	_	NNS	_	_	13	OBJ	_	_
16	in	_	IN	_	_	13	LOC	_	_
17	medical	_	JJ	_	_	20	NMOD	_	_
18	and	_	CC	_	_	17	COORD	_	_
19	biotechnology	_	NN	_	_	18	CONJ	_	_
20	businesses	_	NNS	_	_	16	PMOD	_	_
21	,	_	,	_	_	6	P	_	_
22	according	_	VBG	_	_	6	ADV	_	_
23	to	_	TO	_	_	22	PMOD	_	_
24	the	_	DT	_	_	28	NMOD	_	_
25	National	_	NNP	_	_	28	NAME	_	_
26	Venture	_	NNP	_	_	28	NAME	_	_
27	Capital	_	NNP	_	_	28	NAME	_	_
28	Association	_	NNP	_	_	23	PMOD	_	_
29	,	_	,	_	_	28	P	_	_
30	a	_	DT	_	_	32	NMOD	_	_
31	trade	_	NN	_	_	32	NMOD	_	_
32	group	_	NN	_	_	28	APPO	_	_
33	.	_	.	_	_	6	P	_	_

1	Many	_	JJ	_	_	5	SBJ	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	deals	_	NNS	_	_	2	PMOD	_	_
5	involved	_	VBD	_	_	0	ROOT	_	_
6	transactions	_	NNS	_	_	5	OBJ	_	_
7	in	_	IN	_	_	13	LOC	_	_
8	which	_	WDT	_	_	7	PMOD	_	_
9	scientific	_	JJ	_	_	10	NMOD	_	_
10	institutions	_	NNS	_	_	13	SBJ	_	_
11	or	_	CC	_	_	10	COORD	_	_
12	researchers	_	NNS	_	_	11	CONJ	_	_
13	agreed	_	VBN	_	_	6	NMOD	_	_
14	to	_	TO	_	_	13	OPRD	_	_
15	commercialize	_	VB	_	_	14	IM	_	_
16	their	_	PRP$	_	_	17	NMOD	_	_
17	work	_	NN	_	_	15	OBJ	_	_
18	in	_	IN	_	_	13	ADV	_	_
19	return	_	NN	_	_	18	PMOD	_	_
20	for	_	IN	_	_	19	NMOD	_	_
21	an	_	DT	_	_	23	NMOD	_	_
22	equity	_	NN	_	_	23	NMOD	_	_
23	stake	_	NN	_	_	20	PMOD	_	_
24	or	_	CC	_	_	23	COORD	_	_
25	royalties	_	NNS	_	_	24	CONJ	_	_
26	.	_	.	_	_	5	P	_	_

1	In	_	IN	_	_	10	LOC	_	_
2	many	_	DT	_	_	1	PMOD	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	these	_	DT	_	_	5	NMOD	_	_
5	deals	_	VBZ	_	_	3	PMOD	_	_
6	,	_	,	_	_	10	P	_	_
7	``	_	``	_	_	10	P	_	_
8	venture	_	NN	_	_	9	NMOD	_	_
9	capitalists	_	NNS	_	_	10	SBJ	_	_
10	had	_	VBD	_	_	16	OBJ	_	_
11	the	_	DT	_	_	13	NMOD	_	_
12	inside	_	NN	_	_	13	NMOD	_	_
13	track	_	NN	_	_	10	OBJ	_	_
14	,	_	,	_	_	16	P	_	_
15	''	_	''	_	_	16	P	_	_
16	says	_	VBZ	_	_	0	ROOT	_	_
17	Lawrence	_	NNP	_	_	18	NAME	_	_
18	Bock	_	NNP	_	_	16	SBJ	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	Avalon	_	NNP	_	_	21	NAME	_	_
21	Ventures	_	NNP	_	_	19	PMOD	_	_
22	,	_	,	_	_	21	P	_	_
23	La	_	NNP	_	_	24	NAME	_	_
24	Jolla	_	NNP	_	_	21	LOC	_	_
25	,	_	,	_	_	24	P	_	_
26	Calif	_	NNP	_	_	24	APPO	_	_
27	.	_	.	_	_	16	P	_	_

1	Investors	_	NNS	_	_	2	SBJ	_	_
2	were	_	VBD	_	_	21	OBJ	_	_
3	willing	_	JJ	_	_	2	PRD	_	_
4	to	_	TO	_	_	3	AMOD	_	_
5	gamble	_	VB	_	_	4	IM	_	_
6	on	_	IN	_	_	5	ADV	_	_
7	new	_	JJ	_	_	8	NMOD	_	_
8	technologies	_	NNS	_	_	6	PMOD	_	_
9	because	_	IN	_	_	5	PRP	_	_
10	``	_	``	_	_	9	P	_	_
11	we	_	PRP	_	_	12	SBJ	_	_
12	had	_	VBD	_	_	9	SUB	_	_
13	exclusive	_	JJ	_	_	14	NMOD	_	_
14	rights	_	NNS	_	_	12	OBJ	_	_
15	to	_	TO	_	_	14	NMOD	_	_
16	those	_	DT	_	_	17	NMOD	_	_
17	technologies	_	NNS	_	_	15	PMOD	_	_
18	,	_	,	_	_	21	P	_	_
19	''	_	''	_	_	21	P	_	_
20	he	_	PRP	_	_	21	SBJ	_	_
21	adds	_	VBZ	_	_	0	ROOT	_	_
22	.	_	.	_	_	21	P	_	_

1	But	_	CC	_	_	11	DEP	_	_
2	under	_	IN	_	_	11	LOC	_	_
3	the	_	DT	_	_	5	NMOD	_	_
4	proposed	_	VBN	_	_	5	NMOD	_	_
5	guidelines	_	NNS	_	_	2	PMOD	_	_
6	,	_	,	_	_	11	P	_	_
7	all	_	DT	_	_	10	NMOD	_	_
8	federally	_	RB	_	_	9	AMOD	_	_
9	funded	_	VBN	_	_	10	NMOD	_	_
10	research	_	NN	_	_	11	SBJ	_	_
11	will	_	MD	_	_	0	ROOT	_	_
12	have	_	VB	_	_	11	VC	_	_
13	to	_	TO	_	_	12	OPRD	_	_
14	be	_	VB	_	_	13	IM	_	_
15	reported	_	VBN	_	_	14	VC	_	_
16	publicly	_	RB	_	_	15	MNR	_	_
17	so	_	IN	_	_	15	PRP	_	_
18	that	_	IN	_	_	17	DEP	_	_
19	anyone	_	NN	_	_	20	SBJ	_	_
20	can	_	MD	_	_	17	SUB	_	_
21	capitalize	_	VB	_	_	20	VC	_	_
22	on	_	IN	_	_	21	ADV	_	_
23	the	_	DT	_	_	24	NMOD	_	_
24	work	_	NN	_	_	22	PMOD	_	_
25	.	_	.	_	_	11	P	_	_

1	``	_	``	_	_	23	P	_	_
2	Without	_	IN	_	_	9	ADV	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	exclusivity	_	NN	_	_	2	PMOD	_	_
5	,	_	,	_	_	9	P	_	_
6	most	_	JJS	_	_	8	NMOD	_	_
7	venture	_	NN	_	_	8	NMOD	_	_
8	capitalists	_	NNS	_	_	9	SBJ	_	_
9	wo	_	MD	_	_	23	OBJ	_	_
10	n't	_	RB	_	_	9	ADV	_	_
11	have	_	VB	_	_	9	VC	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	incentive	_	NN	_	_	11	OBJ	_	_
14	to	_	TO	_	_	13	NMOD	_	_
15	invest	_	VB	_	_	14	IM	_	_
16	in	_	IN	_	_	15	ADV	_	_
17	such	_	JJ	_	_	18	NMOD	_	_
18	deals	_	NNS	_	_	16	PMOD	_	_
19	,	_	,	_	_	23	P	_	_
20	''	_	''	_	_	23	P	_	_
21	Mr.	_	NNP	_	_	22	TITLE	_	_
22	Bock	_	NNP	_	_	23	SBJ	_	_
23	says	_	VBZ	_	_	0	ROOT	_	_
24	.	_	.	_	_	23	P	_	_

1	Last	_	JJ	_	_	2	NMOD	_	_
2	year	_	NN	_	_	10	TMP	_	_
3	,	_	,	_	_	10	P	_	_
4	for	_	IN	_	_	10	ADV	_	_
5	example	_	NN	_	_	4	PMOD	_	_
6	,	_	,	_	_	10	P	_	_
7	Avalon	_	NNP	_	_	10	SBJ	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	others	_	NNS	_	_	8	CONJ	_	_
10	invested	_	VBD	_	_	0	ROOT	_	_
11	$	_	$	_	_	10	OBJ	_	_
12	14	_	CD	_	_	11	DEP	_	_
13	million	_	CD	_	_	11	DEP	_	_
14	in	_	IN	_	_	10	LOC	_	_
15	Athena	_	NNP	_	_	16	NAME	_	_
16	Neurosciences	_	NNP	_	_	14	PMOD	_	_
17	Inc.	_	NNP	_	_	16	POSTHON	_	_
18	,	_	,	_	_	16	P	_	_
19	South	_	NNP	_	_	21	NAME	_	_
20	San	_	NNP	_	_	21	NAME	_	_
21	Francisco	_	NNP	_	_	16	LOC	_	_
22	,	_	,	_	_	21	P	_	_
23	Calif.	_	NNP	_	_	21	APPO	_	_
24	,	_	,	_	_	10	P	_	_
25	to	_	TO	_	_	10	PRP	_	_
26	license	_	VB	_	_	25	IM	_	_
27	and	_	CC	_	_	26	COORD	_	_
28	develop	_	VB	_	_	27	CONJ	_	_
29	technology	_	NN	_	_	26	OBJ	_	_
30	for	_	IN	_	_	29	NMOD	_	_
31	delivery	_	NN	_	_	30	PMOD	_	_
32	of	_	IN	_	_	31	NMOD	_	_
33	drugs	_	NNS	_	_	32	PMOD	_	_
34	to	_	TO	_	_	31	NMOD	_	_
35	the	_	DT	_	_	36	NMOD	_	_
36	brain	_	NN	_	_	34	PMOD	_	_
37	.	_	.	_	_	10	P	_	_

1	But	_	CC	_	_	18	DEP	_	_
2	before	_	IN	_	_	18	TMP	_	_
3	Athena	_	NNP	_	_	4	SBJ	_	_
4	was	_	VBD	_	_	2	SUB	_	_
5	able	_	JJ	_	_	4	PRD	_	_
6	to	_	TO	_	_	5	AMOD	_	_
7	get	_	VB	_	_	6	IM	_	_
8	an	_	DT	_	_	10	NMOD	_	_
9	exclusive	_	JJ	_	_	10	NMOD	_	_
10	license	_	NN	_	_	7	OBJ	_	_
11	to	_	TO	_	_	10	NMOD	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	technology	_	NN	_	_	11	PMOD	_	_
14	,	_	,	_	_	18	P	_	_
15	the	_	DT	_	_	17	NMOD	_	_
16	Federal	_	NNP	_	_	17	NAME	_	_
17	Register	_	NNP	_	_	18	SBJ	_	_
18	published	_	VBD	_	_	42	OBJ	_	_
19	most	_	JJS	_	_	18	OBJ	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	details	_	NNS	_	_	20	PMOD	_	_
23	,	_	,	_	_	18	P	_	_
24	``	_	``	_	_	18	P	_	_
25	giving	_	VBG	_	_	18	ADV	_	_
26	all	_	DT	_	_	25	OBJ	_	_
27	of	_	IN	_	_	26	NMOD	_	_
28	the	_	DT	_	_	29	NMOD	_	_
29	company	_	NN	_	_	32	NMOD	_	_
30	's	_	POS	_	_	29	SUFFIX	_	_
31	potential	_	JJ	_	_	32	NMOD	_	_
32	competitors	_	NNS	_	_	27	PMOD	_	_
33	a	_	DT	_	_	34	NMOD	_	_
34	chance	_	NN	_	_	25	OBJ	_	_
35	to	_	TO	_	_	34	NMOD	_	_
36	exploit	_	VB	_	_	35	IM	_	_
37	it	_	PRP	_	_	36	OBJ	_	_
38	,	_	,	_	_	42	P	_	_
39	''	_	''	_	_	42	P	_	_
40	Mr.	_	NNP	_	_	41	TITLE	_	_
41	Bock	_	NNP	_	_	42	SBJ	_	_
42	says	_	VBZ	_	_	0	ROOT	_	_
43	.	_	.	_	_	42	P	_	_

1	Athena	_	NNP	_	_	3	SBJ	_	_
2	eventually	_	RB	_	_	3	TMP	_	_
3	acquired	_	VBD	_	_	0	ROOT	_	_
4	exclusive	_	JJ	_	_	5	NMOD	_	_
5	rights	_	NNS	_	_	3	OBJ	_	_
6	to	_	TO	_	_	5	NMOD	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	technology	_	NN	_	_	6	PMOD	_	_
9	and	_	CC	_	_	3	COORD	_	_
10	currently	_	RB	_	_	11	TMP	_	_
11	is	_	VBZ	_	_	9	CONJ	_	_
12	developing	_	VBG	_	_	11	VC	_	_
13	it	_	PRP	_	_	12	OBJ	_	_
14	.	_	.	_	_	3	P	_	_

1	But	_	CC	_	_	3	DEP	_	_
2	,	_	,	_	_	3	P	_	_
3	says	_	VBZ	_	_	0	ROOT	_	_
4	Mr.	_	NNP	_	_	5	TITLE	_	_
5	Bock	_	NNP	_	_	3	SBJ	_	_
6	,	_	,	_	_	3	P	_	_
7	``	_	``	_	_	3	P	_	_
8	It	_	PRP	_	_	9	SBJ	_	_
9	was	_	VBD	_	_	3	OBJ	_	_
10	a	_	DT	_	_	12	NMOD	_	_
11	close	_	JJ	_	_	12	NMOD	_	_
12	call	_	NN	_	_	9	PRD	_	_
13	.	_	.	_	_	3	P	_	_
14	''	_	''	_	_	3	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	proposed	_	VBN	_	_	3	NMOD	_	_
3	guidelines	_	NNS	_	_	4	SBJ	_	_
4	could	_	MD	_	_	19	OBJ	_	_
5	also	_	RB	_	_	4	ADV	_	_
6	delay	_	VB	_	_	4	VC	_	_
7	commercialization	_	NN	_	_	6	OBJ	_	_
8	--	_	:	_	_	6	P	_	_
9	and	_	CC	_	_	6	COORD	_	_
10	force	_	VB	_	_	9	CONJ	_	_
11	small	_	JJ	_	_	12	NMOD	_	_
12	companies	_	NNS	_	_	10	OBJ	_	_
13	to	_	TO	_	_	10	OPRD	_	_
14	waste	_	VB	_	_	13	IM	_	_
15	scarce	_	JJ	_	_	16	NMOD	_	_
16	capital	_	NN	_	_	14	OBJ	_	_
17	,	_	,	_	_	19	P	_	_
18	entrepreneurs	_	NNS	_	_	19	SBJ	_	_
19	say	_	VBP	_	_	0	ROOT	_	_
20	.	_	.	_	_	19	P	_	_

1	If	_	IN	_	_	17	ADV	_	_
2	start-ups	_	NNS	_	_	3	SBJ	_	_
3	ca	_	MD	_	_	1	SUB	_	_
4	n't	_	RB	_	_	3	ADV	_	_
5	have	_	VB	_	_	3	VC	_	_
6	early	_	JJ	_	_	7	NMOD	_	_
7	access	_	NN	_	_	5	OBJ	_	_
8	to	_	TO	_	_	7	NMOD	_	_
9	research	_	NN	_	_	8	PMOD	_	_
10	being	_	NN	_	_	11	DEP	_	_
11	conducted	_	VBN	_	_	9	APPO	_	_
12	at	_	IN	_	_	11	LOC	_	_
13	institutions	_	NNS	_	_	12	PMOD	_	_
14	,	_	,	_	_	17	P	_	_
15	``	_	``	_	_	17	P	_	_
16	we	_	PRP	_	_	17	SBJ	_	_
17	have	_	VBP	_	_	29	OBJ	_	_
18	to	_	TO	_	_	17	OPRD	_	_
19	replicate	_	VB	_	_	18	IM	_	_
20	it	_	PRP	_	_	19	OBJ	_	_
21	ourselves	_	PRP	_	_	19	ADV	_	_
22	or	_	CC	_	_	19	COORD	_	_
23	do	_	VB	_	_	22	CONJ	_	_
24	without	_	IN	_	_	23	ADV	_	_
25	the	_	DT	_	_	26	NMOD	_	_
26	research	_	NN	_	_	24	PMOD	_	_
27	,	_	,	_	_	29	P	_	_
28	''	_	''	_	_	29	P	_	_
29	says	_	VBZ	_	_	0	ROOT	_	_
30	Ruth	_	NNP	_	_	31	NAME	_	_
31	Emyanitoff	_	NNP	_	_	29	SBJ	_	_
32	,	_	,	_	_	31	P	_	_
33	manager	_	NN	_	_	31	APPO	_	_
34	of	_	IN	_	_	33	NMOD	_	_
35	business	_	NN	_	_	36	NMOD	_	_
36	development	_	NN	_	_	34	PMOD	_	_
37	at	_	IN	_	_	33	LOC	_	_
38	Applied	_	NNP	_	_	39	NAME	_	_
39	bioTechnology	_	NNP	_	_	37	PMOD	_	_
40	Inc.	_	NNP	_	_	39	POSTHON	_	_
41	,	_	,	_	_	39	P	_	_
42	a	_	DT	_	_	47	NMOD	_	_
43	Cambridge	_	NNP	_	_	45	NAME	_	_
44	,	_	,	_	_	45	P	_	_
45	Mass.	_	NNP	_	_	47	LOC	_	_
46	,	_	,	_	_	45	P	_	_
47	concern	_	NN	_	_	39	APPO	_	_
48	.	_	.	_	_	29	P	_	_

1	Duplicating	_	VBG	_	_	3	SBJ	_	_
2	research	_	NN	_	_	1	OBJ	_	_
3	is	_	VBZ	_	_	14	OBJ	_	_
4	both	_	DT	_	_	5	AMOD	_	_
5	costly	_	JJ	_	_	3	PRD	_	_
6	and	_	CC	_	_	5	COORD	_	_
7	time-consuming	_	JJ	_	_	6	CONJ	_	_
8	for	_	IN	_	_	3	ADV	_	_
9	a	_	DT	_	_	10	NMOD	_	_
10	start-up	_	NN	_	_	8	PMOD	_	_
11	,	_	,	_	_	14	P	_	_
12	Ms.	_	NNP	_	_	13	TITLE	_	_
13	Emyanitoff	_	NNP	_	_	14	SBJ	_	_
14	says	_	VBZ	_	_	0	ROOT	_	_
15	.	_	.	_	_	14	P	_	_

1	For	_	IN	_	_	6	ADV	_	_
2	its	_	PRP$	_	_	3	NMOD	_	_
3	part	_	NN	_	_	1	PMOD	_	_
4	,	_	,	_	_	6	P	_	_
5	NIH	_	NNP	_	_	6	SBJ	_	_
6	insists	_	VBZ	_	_	0	ROOT	_	_
7	that	_	IN	_	_	6	OBJ	_	_
8	its	_	PRP$	_	_	9	NMOD	_	_
9	guidelines	_	NNS	_	_	11	SBJ	_	_
10	``	_	``	_	_	11	P	_	_
11	should	_	MD	_	_	7	SUB	_	_
12	not	_	RB	_	_	11	ADV	_	_
13	stifle	_	VB	_	_	11	VC	_	_
14	research	_	NN	_	_	15	NMOD	_	_
15	creativity	_	NN	_	_	13	OBJ	_	_
16	or	_	CC	_	_	15	COORD	_	_
17	technology	_	NN	_	_	18	NMOD	_	_
18	transfer	_	NN	_	_	16	CONJ	_	_
19	from	_	IN	_	_	18	NMOD	_	_
20	the	_	DT	_	_	22	NMOD	_	_
21	research	_	NN	_	_	22	NMOD	_	_
22	laboratory	_	NN	_	_	19	PMOD	_	_
23	to	_	TO	_	_	18	NMOD	_	_
24	commercial	_	JJ	_	_	25	NMOD	_	_
25	use	_	NN	_	_	23	PMOD	_	_
26	.	_	.	_	_	6	P	_	_
27	''	_	''	_	_	6	P	_	_

1	Universities	_	NNS	_	_	7	SBJ	_	_
2	such	_	JJ	_	_	3	DEP	_	_
3	as	_	IN	_	_	1	NMOD	_	_
4	Harvard	_	NNP	_	_	3	PMOD	_	_
5	and	_	CC	_	_	4	COORD	_	_
6	MIT	_	NNP	_	_	5	CONJ	_	_
7	should	_	MD	_	_	23	OBJ	_	_
8	be	_	VB	_	_	7	VC	_	_
9	able	_	JJ	_	_	8	PRD	_	_
10	to	_	TO	_	_	9	AMOD	_	_
11	develop	_	VB	_	_	10	IM	_	_
12	a	_	DT	_	_	13	NMOD	_	_
13	way	_	NN	_	_	11	OBJ	_	_
14	to	_	TO	_	_	13	NMOD	_	_
15	act	_	VB	_	_	14	IM	_	_
16	as	_	IN	_	_	15	ADV	_	_
17	brokers	_	NNS	_	_	16	PMOD	_	_
18	for	_	IN	_	_	17	NMOD	_	_
19	the	_	DT	_	_	21	NMOD	_	_
20	individual	_	JJ	_	_	21	NMOD	_	_
21	scientists	_	NNS	_	_	18	PMOD	_	_
22	,	_	,	_	_	23	P	_	_
23	says	_	VBZ	_	_	0	ROOT	_	_
24	Katherine	_	NNP	_	_	25	NAME	_	_
25	Bick	_	NNP	_	_	23	SBJ	_	_
26	,	_	,	_	_	25	P	_	_
27	who	_	WP	_	_	28	SBJ	_	_
28	oversees	_	VBZ	_	_	25	NMOD	_	_
29	the	_	DT	_	_	33	NMOD	_	_
30	huge	_	JJ	_	_	33	NMOD	_	_
31	NIH	_	NNP	_	_	33	NMOD	_	_
32	grants	_	NNS	_	_	33	NMOD	_	_
33	program	_	NN	_	_	28	OBJ	_	_
34	as	_	IN	_	_	28	MNR	_	_
35	its	_	PRP$	_	_	37	NMOD	_	_
36	deputy	_	NN	_	_	37	NMOD	_	_
37	director	_	NN	_	_	34	PMOD	_	_
38	for	_	IN	_	_	37	NMOD	_	_
39	extramural	_	JJ	_	_	40	NMOD	_	_
40	research	_	NN	_	_	38	PMOD	_	_
41	.	_	.	_	_	23	P	_	_

1	NIH	_	NNP	_	_	3	NMOD	_	_
2	staff	_	NN	_	_	3	NMOD	_	_
3	members	_	NNS	_	_	4	SBJ	_	_
4	believe	_	VBP	_	_	0	ROOT	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	guidelines	_	NNS	_	_	7	SBJ	_	_
7	are	_	VBP	_	_	4	OBJ	_	_
8	essential	_	JJ	_	_	7	PRD	_	_
9	to	_	TO	_	_	8	AMOD	_	_
10	prevent	_	VB	_	_	9	IM	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	escalation	_	NN	_	_	10	OBJ	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	problems	_	NNS	_	_	13	PMOD	_	_
15	that	_	WDT	_	_	16	SBJ	_	_
16	have	_	VBP	_	_	14	NMOD	_	_
17	already	_	RB	_	_	16	ADV	_	_
18	begun	_	VBN	_	_	16	VC	_	_
19	to	_	TO	_	_	18	OPRD	_	_
20	surface	_	VB	_	_	19	IM	_	_
21	in	_	IN	_	_	20	LOC	_	_
22	scientific	_	JJ	_	_	23	NMOD	_	_
23	ventures	_	NNS	_	_	21	PMOD	_	_
24	.	_	.	_	_	4	P	_	_

1	Not	_	RB	_	_	13	TMP	_	_
2	long	_	RB	_	_	1	AMOD	_	_
3	ago	_	RB	_	_	1	AMOD	_	_
4	,	_	,	_	_	13	P	_	_
5	scientists	_	NNS	_	_	13	SBJ	_	_
6	holding	_	VBG	_	_	5	APPO	_	_
7	stock	_	NN	_	_	6	OBJ	_	_
8	in	_	IN	_	_	7	LOC	_	_
9	Spectra	_	NNP	_	_	11	NAME	_	_
10	Pharmaceutical	_	NNP	_	_	11	NAME	_	_
11	Services	_	NNPS	_	_	8	PMOD	_	_
12	Inc.	_	NNP	_	_	11	POSTHON	_	_
13	were	_	VBD	_	_	0	ROOT	_	_
14	accused	_	VBN	_	_	13	VC	_	_
15	of	_	IN	_	_	14	ADV	_	_
16	falsifying	_	VBG	_	_	15	PMOD	_	_
17	research	_	NN	_	_	16	OBJ	_	_
18	to	_	TO	_	_	16	PRP	_	_
19	boost	_	VB	_	_	18	IM	_	_
20	the	_	DT	_	_	21	NMOD	_	_
21	stock	_	NN	_	_	19	OBJ	_	_
22	.	_	.	_	_	13	P	_	_

1	Many	_	JJ	_	_	2	NMOD	_	_
2	officials	_	NNS	_	_	3	SBJ	_	_
3	are	_	VBP	_	_	0	ROOT	_	_
4	also	_	RB	_	_	3	ADV	_	_
5	concerned	_	VBN	_	_	3	PRD	_	_
6	about	_	IN	_	_	5	AMOD	_	_
7	companies	_	NNS	_	_	6	PMOD	_	_
8	getting	_	VBG	_	_	7	APPO	_	_
9	a	_	DT	_	_	12	NMOD	_	_
10	``	_	``	_	_	12	P	_	_
11	free	_	JJ	_	_	12	NMOD	_	_
12	ride	_	NN	_	_	8	OBJ	_	_
13	''	_	''	_	_	12	P	_	_
14	on	_	IN	_	_	12	NMOD	_	_
15	government-sponsored	_	JJ	_	_	16	NMOD	_	_
16	research	_	NN	_	_	14	PMOD	_	_
17	.	_	.	_	_	3	P	_	_

1	A	_	DT	_	_	3	NMOD	_	_
2	congressional	_	JJ	_	_	3	NMOD	_	_
3	subcommitee	_	NN	_	_	4	SBJ	_	_
4	has	_	VBZ	_	_	0	ROOT	_	_
5	been	_	VBN	_	_	4	VC	_	_
6	investigating	_	VBG	_	_	5	VC	_	_
7	the	_	DT	_	_	9	NMOD	_	_
8	potential	_	JJ	_	_	9	NMOD	_	_
9	abuse	_	NN	_	_	6	OBJ	_	_
10	from	_	IN	_	_	9	NMOD	_	_
11	researchers	_	NNS	_	_	10	PMOD	_	_
12	holding	_	VBG	_	_	11	APPO	_	_
13	stock	_	NN	_	_	12	OBJ	_	_
14	in	_	IN	_	_	13	LOC	_	_
15	companies	_	NNS	_	_	14	PMOD	_	_
16	exploiting	_	VBG	_	_	15	APPO	_	_
17	their	_	PRP$	_	_	18	NMOD	_	_
18	research	_	NN	_	_	16	OBJ	_	_
19	.	_	.	_	_	4	P	_	_

1	Among	_	IN	_	_	8	ADV	_	_
2	other	_	JJ	_	_	3	NMOD	_	_
3	provisions	_	NNS	_	_	1	PMOD	_	_
4	,	_	,	_	_	8	P	_	_
5	the	_	DT	_	_	7	NMOD	_	_
6	NIH	_	NNP	_	_	7	NMOD	_	_
7	guidelines	_	NNS	_	_	8	SBJ	_	_
8	would	_	MD	_	_	0	ROOT	_	_
9	prohibit	_	VB	_	_	8	VC	_	_
10	researchers	_	NNS	_	_	9	OBJ	_	_
11	and	_	CC	_	_	10	COORD	_	_
12	members	_	NNS	_	_	11	CONJ	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	their	_	PRP$	_	_	16	NMOD	_	_
15	immediate	_	JJ	_	_	16	NMOD	_	_
16	families	_	NNS	_	_	13	PMOD	_	_
17	from	_	IN	_	_	9	ADV	_	_
18	holding	_	VBG	_	_	17	PMOD	_	_
19	stock	_	NN	_	_	18	OBJ	_	_
20	in	_	IN	_	_	19	LOC	_	_
21	any	_	DT	_	_	22	NMOD	_	_
22	company	_	NN	_	_	20	PMOD	_	_
23	that	_	WDT	_	_	24	SBJ	_	_
24	is	_	VBZ	_	_	22	NMOD	_	_
25	affected	_	VBN	_	_	24	VC	_	_
26	by	_	IN	_	_	25	LGS	_	_
27	the	_	DT	_	_	28	NMOD	_	_
28	outcome	_	NN	_	_	26	PMOD	_	_
29	of	_	IN	_	_	28	NMOD	_	_
30	their	_	PRP$	_	_	31	NMOD	_	_
31	research	_	NN	_	_	29	PMOD	_	_
32	.	_	.	_	_	8	P	_	_

1	Ms.	_	NNP	_	_	2	TITLE	_	_
2	Bick	_	NNP	_	_	8	SBJ	_	_
3	,	_	,	_	_	2	P	_	_
4	the	_	DT	_	_	6	NMOD	_	_
5	NIH	_	NNP	_	_	6	NMOD	_	_
6	administrator	_	NN	_	_	2	APPO	_	_
7	,	_	,	_	_	2	P	_	_
8	says	_	VBZ	_	_	0	ROOT	_	_
9	the	_	DT	_	_	13	NMOD	_	_
10	business	_	NN	_	_	13	NMOD	_	_
11	and	_	CC	_	_	10	COORD	_	_
12	scientific	_	JJ	_	_	11	CONJ	_	_
13	community	_	NN	_	_	14	SBJ	_	_
14	is	_	VBZ	_	_	8	OBJ	_	_
15	overreacting	_	VBG	_	_	14	VC	_	_
16	to	_	TO	_	_	15	ADV	_	_
17	what	_	WP	_	_	21	OBJ	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	agency	_	NN	_	_	21	SBJ	_	_
20	merely	_	RB	_	_	21	ADV	_	_
21	meant	_	VBD	_	_	16	PMOD	_	_
22	to	_	TO	_	_	21	OPRD	_	_
23	be	_	VB	_	_	22	IM	_	_
24	``	_	``	_	_	23	P	_	_
25	ideas	_	NNS	_	_	23	PRD	_	_
26	for	_	IN	_	_	25	NMOD	_	_
27	discussion	_	NN	_	_	26	PMOD	_	_
28	.	_	.	_	_	8	P	_	_
29	''	_	''	_	_	8	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	predictions	_	NNS	_	_	5	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	doom	_	NN	_	_	3	PMOD	_	_
5	are	_	VBP	_	_	11	OBJ	_	_
6	``	_	``	_	_	5	P	_	_
7	premature	_	JJ	_	_	5	PRD	_	_
8	,	_	,	_	_	11	P	_	_
9	''	_	''	_	_	11	P	_	_
10	she	_	PRP	_	_	11	SBJ	_	_
11	says	_	VBZ	_	_	0	ROOT	_	_
12	.	_	.	_	_	11	P	_	_

1	But	_	CC	_	_	11	DEP	_	_
2	when	_	WRB	_	_	7	TMP	_	_
3	agencies	_	NNS	_	_	7	SBJ	_	_
4	like	_	IN	_	_	3	NMOD	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	NIH	_	NNP	_	_	4	PMOD	_	_
7	circulate	_	VBP	_	_	11	TMP	_	_
8	guidelines	_	NNS	_	_	7	OBJ	_	_
9	,	_	,	_	_	11	P	_	_
10	they	_	PRP	_	_	11	SBJ	_	_
11	've	_	VBP	_	_	19	OBJ	_	_
12	often	_	RB	_	_	11	TMP	_	_
13	already	_	RB	_	_	11	ADV	_	_
14	formulated	_	VBN	_	_	11	VC	_	_
15	policy	_	NN	_	_	14	OBJ	_	_
16	,	_	,	_	_	19	P	_	_
17	veteran	_	NN	_	_	18	NMOD	_	_
18	scientists	_	NNS	_	_	19	SBJ	_	_
19	say	_	VBP	_	_	0	ROOT	_	_
20	.	_	.	_	_	19	P	_	_

1	Indeed	_	RB	_	_	5	ADV	_	_
2	,	_	,	_	_	5	P	_	_
3	institutions	_	NNS	_	_	5	SBJ	_	_
4	already	_	RB	_	_	5	ADV	_	_
5	are	_	VBP	_	_	0	ROOT	_	_
6	taking	_	VBG	_	_	5	VC	_	_
7	note	_	NN	_	_	6	OBJ	_	_
8	.	_	.	_	_	5	P	_	_

1	On	_	IN	_	_	6	TMP	_	_
2	Sept.	_	NNP	_	_	1	PMOD	_	_
3	14	_	CD	_	_	2	NMOD	_	_
4	,	_	,	_	_	6	P	_	_
5	Harvard	_	NNP	_	_	6	SBJ	_	_
6	began	_	VBD	_	_	0	ROOT	_	_
7	circulating	_	VBG	_	_	6	OPRD	_	_
8	a	_	DT	_	_	11	NMOD	_	_
9	conflict-of-interest	_	JJ	_	_	11	NMOD	_	_
10	policy	_	NN	_	_	11	NMOD	_	_
11	statement	_	NN	_	_	7	OBJ	_	_
12	that	_	IN	_	_	17	SBJ	_	_
13	,	_	,	_	_	17	P	_	_
14	in	_	IN	_	_	17	ADV	_	_
15	effect	_	NN	_	_	14	PMOD	_	_
16	,	_	,	_	_	17	P	_	_
17	would	_	MD	_	_	11	NMOD	_	_
18	follow	_	VB	_	_	17	VC	_	_
19	the	_	DT	_	_	21	NMOD	_	_
20	NIH	_	NNP	_	_	21	NMOD	_	_
21	guidelines	_	NNS	_	_	18	OBJ	_	_
22	faithfully	_	RB	_	_	18	MNR	_	_
23	.	_	.	_	_	6	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	University	_	NNP	_	_	8	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	California	_	NNP	_	_	3	PMOD	_	_
5	at	_	IN	_	_	2	LOC	_	_
6	San	_	NNP	_	_	7	NAME	_	_
7	Francisco	_	NNP	_	_	5	PMOD	_	_
8	is	_	VBZ	_	_	0	ROOT	_	_
9	also	_	RB	_	_	8	ADV	_	_
10	circulating	_	VBG	_	_	8	VC	_	_
11	a	_	DT	_	_	12	NMOD	_	_
12	memo	_	NN	_	_	10	OBJ	_	_
13	among	_	IN	_	_	10	ADV	_	_
14	its	_	PRP$	_	_	16	NMOD	_	_
15	scientific	_	JJ	_	_	16	NMOD	_	_
16	faculty	_	NN	_	_	13	PMOD	_	_
17	that	_	WDT	_	_	18	SBJ	_	_
18	will	_	MD	_	_	12	NMOD	_	_
19	restrict	_	VB	_	_	18	VC	_	_
20	contact	_	NN	_	_	19	OBJ	_	_
21	with	_	IN	_	_	20	NMOD	_	_
22	the	_	DT	_	_	23	NMOD	_	_
23	world	_	NN	_	_	21	PMOD	_	_
24	of	_	IN	_	_	23	NMOD	_	_
25	business	_	NN	_	_	24	PMOD	_	_
26	.	_	.	_	_	8	P	_	_

1	In	_	IN	_	_	7	LOC	_	_
2	many	_	JJ	_	_	4	NMOD	_	_
3	other	_	JJ	_	_	4	NMOD	_	_
4	institutions	_	NNS	_	_	1	PMOD	_	_
5	,	_	,	_	_	7	P	_	_
6	scientists	_	NNS	_	_	7	SBJ	_	_
7	are	_	VBP	_	_	0	ROOT	_	_
8	shunning	_	VBG	_	_	7	VC	_	_
9	contacts	_	NNS	_	_	8	OBJ	_	_
10	with	_	IN	_	_	9	NMOD	_	_
11	venture	_	NN	_	_	12	NMOD	_	_
12	investors	_	NNS	_	_	10	PMOD	_	_
13	until	_	IN	_	_	8	TMP	_	_
14	the	_	DT	_	_	16	NMOD	_	_
15	NIH	_	NNP	_	_	16	NMOD	_	_
16	policy	_	NN	_	_	17	SBJ	_	_
17	is	_	VBZ	_	_	13	SUB	_	_
18	settled	_	VBN	_	_	17	VC	_	_
19	.	_	.	_	_	7	P	_	_

1	Says	_	VBZ	_	_	0	ROOT	_	_
2	Mr.	_	NNP	_	_	3	TITLE	_	_
3	Daly	_	NNP	_	_	1	SBJ	_	_
4	,	_	,	_	_	3	P	_	_
5	the	_	DT	_	_	7	NMOD	_	_
6	venture	_	NN	_	_	7	NMOD	_	_
7	capitalist	_	NN	_	_	3	APPO	_	_
8	:	_	:	_	_	1	P	_	_
9	``	_	``	_	_	1	P	_	_
10	It	_	PRP	_	_	11	SBJ	_	_
11	does	_	VBZ	_	_	1	OBJ	_	_
12	n't	_	RB	_	_	11	ADV	_	_
13	matter	_	VB	_	_	11	VC	_	_
14	whether	_	IN	_	_	13	EXTR	_	_
15	they	_	PRP	_	_	16	SBJ	_	_
16	call	_	VBP	_	_	14	SUB	_	_
17	it	_	PRP	_	_	16	OBJ	_	_
18	guidelines	_	NNS	_	_	16	OPRD	_	_
19	or	_	CC	_	_	18	COORD	_	_
20	policy	_	NN	_	_	19	CONJ	_	_
21	.	_	.	_	_	1	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	damage	_	NN	_	_	3	SBJ	_	_
3	is	_	VBZ	_	_	0	ROOT	_	_
4	already	_	RB	_	_	3	ADV	_	_
5	done	_	VBN	_	_	3	VC	_	_
6	.	_	.	_	_	3	P	_	_

